Trial Outcomes & Findings for Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol (NCT NCT04746989)
NCT ID: NCT04746989
Last Updated: 2026-02-27
Results Overview
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Recruitment status
COMPLETED
Target enrollment
294878 participants
Primary outcome timeframe
Median follow up times: 1) 36 days (exp), 214 days (ref) 2) 1095 days (exp), 1095 days (ref) 3) 565 days (exp), 372 days (ref) 4) 36 days (exp), 248 days (ref)
Results posted on
2026-02-27
Participant Flow
Participant milestones
| Measure |
Probenecid
Exposure group
Probenecid: Probenecid claim is used as the exposure group.
|
Allopurinol
Reference group
Allopurinol: Allopurinol claim is used as the reference group.
|
|---|---|---|
|
Overall Study
STARTED
|
8115
|
286763
|
|
Overall Study
COMPLETED
|
8115
|
8115
|
|
Overall Study
NOT COMPLETED
|
0
|
278648
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol
Baseline characteristics by cohort
| Measure |
Probenecid
n=8115 Participants
Exposure group
Probenecid: Probenecid claim is used as the exposure group.
|
Allopurinol
n=8115 Participants
Reference group
Allopurinol: Allopurinol claim is used as the reference group.
|
Total
n=16230 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=24 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=24 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Age, Categorical
>=65 years
|
8115 Participants
n=24 Participants
|
8115 Participants
n=20 Participants
|
16230 Participants
n=40 Participants
|
|
Age, Continuous
|
75.05 years
STANDARD_DEVIATION 7.20 • n=24 Participants
|
75.16 years
STANDARD_DEVIATION 7.23 • n=20 Participants
|
75.10 years
STANDARD_DEVIATION 7.21 • n=40 Participants
|
|
Sex: Female, Male
Female
|
3735 Participants
n=24 Participants
|
3805 Participants
n=20 Participants
|
7540 Participants
n=40 Participants
|
|
Sex: Female, Male
Male
|
4380 Participants
n=24 Participants
|
4310 Participants
n=20 Participants
|
8690 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
White
|
6404 Participants
n=24 Participants
|
6407 Participants
n=20 Participants
|
12811 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Black
|
1145 Participants
n=24 Participants
|
1180 Participants
n=20 Participants
|
2325 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Asian
|
288 Participants
n=24 Participants
|
256 Participants
n=20 Participants
|
544 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
97 Participants
n=24 Participants
|
97 Participants
n=20 Participants
|
194 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Native American
|
20 Participants
n=24 Participants
|
25 Participants
n=20 Participants
|
45 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Other
|
142 Participants
n=24 Participants
|
137 Participants
n=20 Participants
|
279 Participants
n=40 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
19 Participants
n=24 Participants
|
13 Participants
n=20 Participants
|
32 Participants
n=40 Participants
|
|
Dementia risk factors
Diabetes
|
3473 Participants
n=24 Participants
|
3379 Participants
n=20 Participants
|
6852 Participants
n=40 Participants
|
|
Dementia risk factors
Obesity
|
1038 Participants
n=24 Participants
|
1002 Participants
n=20 Participants
|
2040 Participants
n=40 Participants
|
|
Dementia risk factors
Hypertension
|
7346 Participants
n=24 Participants
|
7324 Participants
n=20 Participants
|
14670 Participants
n=40 Participants
|
|
Dementia risk factors
Coronary Artery Disease
|
3217 Participants
n=24 Participants
|
3201 Participants
n=20 Participants
|
6418 Participants
n=40 Participants
|
|
Dementia risk factors
Depression
|
692 Participants
n=24 Participants
|
668 Participants
n=20 Participants
|
1360 Participants
n=40 Participants
|
|
Dementia risk factors
Anxiety
|
670 Participants
n=24 Participants
|
662 Participants
n=20 Participants
|
1332 Participants
n=40 Participants
|
|
Dementia risk factors
Bipolar disorder
|
43 Participants
n=24 Participants
|
41 Participants
n=20 Participants
|
84 Participants
n=40 Participants
|
|
Dementia risk factors
Schizophrenia
|
21 Participants
n=24 Participants
|
24 Participants
n=20 Participants
|
45 Participants
n=40 Participants
|
PRIMARY outcome
Timeframe: Median follow up times: 1) 36 days (exp), 214 days (ref) 2) 1095 days (exp), 1095 days (ref) 3) 565 days (exp), 372 days (ref) 4) 36 days (exp), 248 days (ref)Population: Study cohort after 1:1 propensity score matching
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Outcome measures
| Measure |
Probenecid
n=8115 Participants
Exposure group
Probenecid: Probenecid claim is used as the exposure group.
|
Allopurinol
n=8115 Participants
Reference group
Allopurinol: Allopurinol claim is used as the reference group.
|
|---|---|---|
|
Time to Dementia Onset
Analysis 1
|
14.44 Incidence rate per 1000 person year
Interval 11.46 to 17.94
|
18.23 Incidence rate per 1000 person year
Interval 16.0 to 20.69
|
|
Time to Dementia Onset
Analysis 2
|
22.07 Incidence rate per 1000 person year
Interval 18.71 to 25.85
|
19.40 Incidence rate per 1000 person year
Interval 16.25 to 23.0
|
|
Time to Dementia Onset
Analysis 3
|
15.87 Incidence rate per 1000 person year
Interval 12.56 to 19.78
|
17.54 Incidence rate per 1000 person year
Interval 13.62 to 22.24
|
|
Time to Dementia Onset
Analysis 4
|
4.96 Incidence rate per 1000 person year
Interval 3.29 to 7.16
|
6.29 Incidence rate per 1000 person year
Interval 5.02 to 7.79
|
Adverse Events
Probenecid
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Allopurinol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER